JP2024536863A - イミダゾピリダジンil-17阻害剤化合物 - Google Patents

イミダゾピリダジンil-17阻害剤化合物 Download PDF

Info

Publication number
JP2024536863A
JP2024536863A JP2024518817A JP2024518817A JP2024536863A JP 2024536863 A JP2024536863 A JP 2024536863A JP 2024518817 A JP2024518817 A JP 2024518817A JP 2024518817 A JP2024518817 A JP 2024518817A JP 2024536863 A JP2024536863 A JP 2024536863A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
substituted
unsubstituted
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536863A5 (cg-RX-API-DMAC7.html
Inventor
ディー. ゴールドバーグ,スティーブン
ゴードン,ディーン
エー. ロスコット,スティーブン
マッカーヴァー,ステファン
ピー. メドゥナ,スティーブン
ティー. シャーマン,ブロック
イー. ヴァルデス,アレクサンダー
ウー,ドンペイ
シュー,シャオファ
イー. ハンナ,ルーク
ディー. ヴェナブル,ジェニファー
シー. ビーヘナ,ダグラス
Original Assignee
ヤンセン ファーマシューティカ エヌ.ベー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ.ベー. filed Critical ヤンセン ファーマシューティカ エヌ.ベー.
Publication of JP2024536863A publication Critical patent/JP2024536863A/ja
Publication of JP2024536863A5 publication Critical patent/JP2024536863A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024518817A 2021-09-27 2022-09-26 イミダゾピリダジンil-17阻害剤化合物 Pending JP2024536863A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163248563P 2021-09-27 2021-09-27
US63/248,563 2021-09-27
US202163273407P 2021-10-29 2021-10-29
US63/273,407 2021-10-29
US202263371910P 2022-08-19 2022-08-19
US63/371,910 2022-08-19
PCT/US2022/077000 WO2023049886A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Publications (2)

Publication Number Publication Date
JP2024536863A true JP2024536863A (ja) 2024-10-08
JP2024536863A5 JP2024536863A5 (cg-RX-API-DMAC7.html) 2025-09-19

Family

ID=83693127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518817A Pending JP2024536863A (ja) 2021-09-27 2022-09-26 イミダゾピリダジンil-17阻害剤化合物

Country Status (10)

Country Link
US (2) US12215111B2 (cg-RX-API-DMAC7.html)
EP (1) EP4408529A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536863A (cg-RX-API-DMAC7.html)
KR (1) KR20240082371A (cg-RX-API-DMAC7.html)
AU (1) AU2022348938A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233625A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003770A (cg-RX-API-DMAC7.html)
TW (1) TW202329933A (cg-RX-API-DMAC7.html)
UY (1) UY39957A (cg-RX-API-DMAC7.html)
WO (1) WO2023049886A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026505057A (ja) * 2023-01-30 2026-02-10 ダイス・アルファ・インコーポレイテッド ベンズイミダゾール及びアザ-ベンズイミダゾール系のil-17aモジュレータ並びにその使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022348938A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
WO2024138286A1 (en) * 2022-12-26 2024-07-04 Usynova Pharmaceuticals, Ltd. Il-17a modulators
EP4688156A1 (en) * 2023-03-28 2026-02-11 Janssen Pharmaceutica NV Lactam-containing imidazopyridazine il-17 inhibitor compounds
WO2025202922A1 (en) * 2024-03-27 2025-10-02 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146194A1 (en) * 2019-01-07 2020-07-16 Eli Lilly And Company Imidazo[1,2-b]pyridazine il-17a inhibitors
WO2020261141A1 (en) * 2019-06-26 2020-12-30 UCB Biopharma SRL Imidazopyridine derivatives as il-17 modulators
CN112341450A (zh) * 2019-08-09 2021-02-09 成都先导药物开发股份有限公司 一种免疫调节剂
JP2021510707A (ja) * 2018-01-15 2021-04-30 ユーシービー バイオファルマ エスアールエル Il−17モジュレータとしての縮合イミダゾール誘導体
CN112824398A (zh) * 2019-11-20 2021-05-21 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170627A1 (en) * 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7664947B2 (ja) 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
AU2022348938A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
CN116143777A (zh) 2021-11-04 2023-05-23 四川海思科制药有限公司 一种可抑制il-17a的杂环化合物及其用途
WO2023078319A1 (zh) 2021-11-04 2023-05-11 海思科医药集团股份有限公司 一种可抑制il-17a的杂环化合物及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510707A (ja) * 2018-01-15 2021-04-30 ユーシービー バイオファルマ エスアールエル Il−17モジュレータとしての縮合イミダゾール誘導体
WO2020146194A1 (en) * 2019-01-07 2020-07-16 Eli Lilly And Company Imidazo[1,2-b]pyridazine il-17a inhibitors
WO2020261141A1 (en) * 2019-06-26 2020-12-30 UCB Biopharma SRL Imidazopyridine derivatives as il-17 modulators
CN112341450A (zh) * 2019-08-09 2021-02-09 成都先导药物开发股份有限公司 一种免疫调节剂
CN112824398A (zh) * 2019-11-20 2021-05-21 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170627A1 (en) * 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026505057A (ja) * 2023-01-30 2026-02-10 ダイス・アルファ・インコーポレイテッド ベンズイミダゾール及びアザ-ベンズイミダゾール系のil-17aモジュレータ並びにその使用

Also Published As

Publication number Publication date
MX2024003770A (es) 2024-06-19
CA3233625A1 (en) 2023-03-30
WO2023049886A1 (en) 2023-03-30
TW202329933A (zh) 2023-08-01
US20250206744A1 (en) 2025-06-26
US20230147458A1 (en) 2023-05-11
UY39957A (es) 2023-04-14
EP4408529A1 (en) 2024-08-07
KR20240082371A (ko) 2024-06-10
US12215111B2 (en) 2025-02-04
AU2022348938A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
US12215111B2 (en) Imidazopyridazine IL-17 inhibitor compounds
JP6862495B2 (ja) Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置
DK3077395T3 (en) PYRROLO [2,3-D] PYRIMIDINYL, PYRROLO [2,3-B] PYRAZINYL AND PYRROLO [2,3-D] PYRIDINYL ACRYLAMIDS
US20100216762A1 (en) Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof
US8217027B2 (en) Sphingosine-1-phosphate receptor agonist and antagonist compounds
TW202330530A (zh) 咪唑并嗒𠯤il-17抑制劑化合物(二)
CA3181676A1 (en) Imidazopyridazines as modulators of il-17
JP7661361B2 (ja) Il-17のモジュレーターとしてのイミダゾピリミジン
KR20090095659A (ko) 스핑고신-1-포스페이트 수용체 효능제 및 길항제 화합물
JP6837072B2 (ja) 6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド化合物
JP2024536868A (ja) ベンズイミダゾール及びアザベンズイミダゾールil-17阻害剤化合物
CN107513067A (zh) 含有取代环戊基的吡咯并嘧啶化合物
TW202327611A (zh) 使用btk抑制劑和p13激酶抑制劑的組合治療癌症之方法
CN118076606A (zh) 咪唑并哒嗪il-17抑制剂化合物
EA049269B1 (ru) Соединения ингибиторов il-17 на основе имидазопиридазина
CN118317962A (zh) 咪唑并哒嗪il-17抑制剂化合物
HK1262295B (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260609